Clinical and genetic features of Chinese pediatric patients with severe congenital protein C deficiency who first presented with purpura fulminans: A case series study and literature review

Thromb Res. 2022 Feb:210:70-77. doi: 10.1016/j.thromres.2021.12.026. Epub 2022 Jan 3.

Abstract

Introduction: Purpura fulminans (PF) is a hematological emergency that can be caused by severe congenital protein C (PC) deficiency. It has been rarely reported in the Chinese population. We aimed to characterize the clinical and genetic features of Chinese pediatric patients with severe congenital PC deficiency who first presented with PF.

Materials and methods: Twelve pediatric patients were diagnosed with severe congenital PC deficiency with PF, which was diagnosed based on our hospital records and previous reports from 1988 to July 2021 in China. We evaluated the clinical and genetic features of these patients.

Results: Nine patients (9/12, 75%) had onsets that were observed within the first 48 h after birth. Six patients had a family history of thromboembolism. There was no consanguinity. Other symptoms were intracranial thrombosis or hemorrhage (4, 33.3%), ocular lesions (2, 16.7%), gastrointestinal hemorrhage (2, 16.7%) and kidney infarction before birth (1, 8.3%). All but one of the patients (one case not detected) had a plasma PC activity of <10%. The genetic study indicated that in the eight patients with inherited PC deficiency, two were homozygous, five were compound heterozygous and one was heterozygous for PC deficiency.

Conclusion: This is the first and largest case series of Chinese pediatric patients with severe congenital PC deficiency who first presented with PF. It has been shown that treatment with both fresh frozen plasma and anticoagulants is recommended when PC concentrate is not easily available, especially in developing countries.

Keywords: Anticoagulants; Congenital protein C deficiency; Fresh frozen plasma replacement; Purpura fulminans.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Anticoagulants / therapeutic use
  • Child
  • Humans
  • Protein C / metabolism
  • Protein C Deficiency* / complications
  • Protein C Deficiency* / genetics
  • Purpura Fulminans* / drug therapy
  • Purpura Fulminans* / genetics
  • Thrombophilia* / drug therapy

Substances

  • Anticoagulants
  • Protein C